SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- The Breast journal published new data from a prospective study conducted at the Seoul National University College of Medicine in Korea that shows Positron Emission Mammography (PEM) has a higher sensitivity for tumor detection compared to whole-body PET/CT when using both visual as well as quantitative analysis. These results were particularly striking and significant for smaller-sized tumors (less than 2 cm), likely due to the improved spatial resolution offered by PEM. This demonstrates PEM’s clinical utility in being able to more effectively diagnosis early stage cancer.
According to recent journal articles, the sensitivity of PET/CT is limited especially for low-grade and small tumors. Most PET/CT scanners currently provide a spatial resolution at 5 mm or greater; thus limiting PET/CT’s ability to depict small-sized tumors such as invasive lobular carcinoma or ductal carcinoma in situ. This study provides a direct comparison within the same patient population.
A total of 113 breast lesions from 101 patients with a mean tumor size of 2.2 cm, were included in the analysis. The patients underwent PEM with FDG and whole-body PET/CT before surgical resection. The images were then analyzed visually and quantitatively using the tumor-to-normal tissue uptake ratio (TNR) with a cutoff of 2.5 or greater. The tumors were classified into 4 groups based on size using pathology measurements prior to detection sensitivity analysis for PEM and PET/CT. In visual analysis, the overall sensitivity of PEM was 95%, which was significantly higher than the 87% sensitivity found for PET/CT; ( p=0.004). In addition, the TNR of PEM was significantly higher than that of PET/CT in small tumors (<1 cm; p=0.005 and <2 cm; p<0.001).
PEM is the breast application of the Naviscan high-resolution PET scanner which both can localize as well as characterize the metabolic activity of a lesion. PEM uses parallel photon detectors in a configuration similar to mammography with breast immobilization, not compression. It is the only FDA-cleared, CE Certified 3D Molecular Breast Imaging (MBI) device on the market. The metabolic view assists physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.
For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) athttp://prst.co/BC
SOURCE Naviscan, Inc.
